H E Bays

Summary

Publications

  1. Bays H, Maki K, McKenney J, Snipes R, Meadowcroft A, Schroyer R, et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010;26:907-15 pubmed publisher
    ..26 mmol/L and 5.64 mmol/L). NCT00903409. ..
  2. Bays H, Braeckman R, Ballantyne C, Kastelein J, Otvos J, Stirtan W, et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol. 2012;6:565-72 pubmed publisher
    ..nct01047683. ..
  3. Bays H, Averna M, Majul C, Muller Wieland D, De Pellegrin A, Giezek H, et al. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol. 2013;112:1885-95 pubmed publisher
  4. request reprint
    Bays H, Goldberg R. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther. 2007;14:567-80 pubmed
  5. request reprint
    Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009;25:671-81 pubmed
    ..Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials. ..
  6. Bays H, McKenney J, Maki K, Doyle R, Carter R, Stein E. Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010;85:122-8 pubmed publisher
    ..Prescription omega-3-acid ethyl esters plus atorvastatin produced significant improvements in non-HDL-C and other lipid parameters in patients with elevated non-HDL-C and triglyceride levels. ..
  7. Bays H, Schwartz S, Littlejohn T, Kerzner B, Krauss R, Karpf D, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011;96:2889-97 pubmed publisher
    ..MBX-8025 also reduced liver enzyme levels. MBX-8025, a novel PPAR-? agonist, favorably affected multiple metabolic parameters with and without atorvastatin. A more complete understanding of MBX-8025 requires a larger future study. ..
  8. Bays H. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther. 2011;9:265-77 pubmed publisher
    ..This article profiles lorcaserin as an illustrative example of general drug development regulatory processes, and specifically details the unique challenge of weight-loss drug development. ..
  9. request reprint
    Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D. 2006;7:289-302 pubmed

More Information

Publications23

  1. Bays H, Jones P, Brown W, Jacobson T. National Lipid Association Annual Summary of Clinical Lipidology 2015. J Clin Lipidol. 2014;8:S1-36 pubmed publisher
  2. Bays H, Conard S, Leiter L, Bird S, Jensen E, Hanson M, et al. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids Health Dis. 2010;9:136 pubmed publisher
    ..Registered at clinicaltrials.gov: Clinical trial # NCT00276484). ..
  3. Bays H, Jones P, Jacobson T, Cohen D, Orringer C, Kothari S, et al. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol. 2016;10:33-57 pubmed publisher
    ..This document represents the full report of part 1. ..
  4. Bays H. A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. J Clin Lipidol. 2016;10:228-39 pubmed publisher
  5. Bays H, Jones P, Jacobson T, Cohen D, Orringer C, Kothari S, et al. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. J Clin Lipidol. 2016;10:15-32 pubmed publisher
    ..This document represents the executive summary of part 1. ..
  6. Bays H. A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. J Clin Lipidol. 2016;10:240-64 pubmed publisher
  7. request reprint
    Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther. 2005;3:393-404 pubmed
    ..Adiposopathy is a plausible Theory of Everything for mankind's greatest metabolic epidemics. ..
  8. Bays H, Ballantyne C, Doyle R, Juliano R, Philip S. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016;125:57-64 pubmed publisher
    ..These studies support icosapent ethyl as producing predictable dose-dependent pharmacokinetics/pharmacodynamics, with TG level lowering dependent upon icosapent ethyl dose and EPA concentrations in plasma and RBCs. ..
  9. Bays H, Jones P, Orringer C, Brown W, Jacobson T. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016;10:S1-43 pubmed publisher
  10. Bays H, Davidson M, Massaad R, Flaim D, Lowe R, Tershakovec A, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011;108:523-30 pubmed publisher
  11. request reprint
    Bays H, McElhattan J, Bryzinski B. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2007;4:181-93 pubmed
    ..In summary, tesaglitazar provided similar glycaemic control to pioglitazone, was associated with significant improvement in lipid and lipoprotein variables, and increased serum creatinine in a dose-dependent manner. ..
  12. Bays H, Gadde K. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc). 2011;47:903-14 pubmed publisher
    ..Reported adverse events with this combination agent are as expected, based upon knowledge of the individual components...
  13. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8:1777-801 pubmed publisher
  14. Bays H, Fox K, Grandy S. Anthropometric measurements and diabetes mellitus: clues to the "pathogenic" and "protective" potential of adipose tissue. Metab Syndr Relat Disord. 2010;8:307-15 pubmed publisher